Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Amphastar Pharmaceuticals, Inc. on June 7, 2018. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data.
Material Changes
No material financial changes are reported in this document. The filing details the outcomes of two stockholder proposals:
- Election of Directors: Three Class II directors (Mary Ziping Luo, Howard Lee, and Michael A. Zasloff) were elected to serve until the 2021 annual meeting.
- Ratification of Auditors: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It strictly reports the voting results of the Annual Meeting.
Investor Verification Checklist
- Verify the specific vote counts for the three director nominees, noting significant "Against" votes (approx. 6 million each) and broker non-votes (approx. 8.8 million each).
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2018 fiscal year.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K does not provide them.